Drug Development for Neurodegenerative Diseases

Dear Colleagues,

Neuropsychiatric disorders such as Parkinson's disease, schizophrenia, depression, and dementia are the most frequent diseases with a substantial loss of productivity and life quality and significant morbidity. Thus, continued efforts for discovering new treatments are needed to improve the lives of these neuropsychiatric disorder patients. Now, clinical failure in the process of drug discovery for neurodegenerative diseases is a common occurrence. As the population continues to age, the incidence of these diseases will also increase. As a result, the need for improved treatments for neuropsychiatric disorders will follow. So, new drug discovery for these diseases remains a hot topic.

This Special Issue aims to provide a platform for original research papers, short communications, and review articles on latest advances in drug development for neurodegenerative diseases, and potentially showing additional disease-modifying properties to address neurodegeneration. These papers may cover multidisciplinary aspects (such as drug design, synthesis, and pharmacological evaluation) of novel drugs with potential therapeutic innovations.

Prof. Dr. Zhongzhen Zhou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.